Eyevensys goal is to build a high-value product pipeline based on its proprietary EyeCET platform enabling the production of a number of therapeutic proteins in the eye, thus improving clinical outcome and reducing the burden of current treatments in a range of important ophthalmic diseases.

Eyevensys is developing a pre-clinical pipeline based on therapeutic proteins that have been shown to be effective in animal models, and which have successfully been expressed in the eye using the EyeCET platform. Opportunities for the EyeCET technology are numerous and could lead to drug candidates treating diseases such as diabetic macular oedema, iCRVO, retinitis pigmentosa and dry AMD/geographic atrophy, or AMD.